Neuburgh Advisers LLC Cuts Stake in Amgen, Inc. (AMGN)
Neuburgh Advisers LLC decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 37.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,948 shares of the medical research company’s stock after selling 15,070 shares during the period. Neuburgh Advisers LLC’s holdings in Amgen were worth $4,605,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in AMGN. HC Financial Advisors Inc. acquired a new stake in Amgen during the fourth quarter valued at $1,924,000. Global X Management Co. LLC boosted its position in Amgen by 17.1% during the first quarter. Global X Management Co. LLC now owns 4,601 shares of the medical research company’s stock valued at $784,000 after purchasing an additional 672 shares during the last quarter. SG Americas Securities LLC boosted its position in Amgen by 452.4% during the first quarter. SG Americas Securities LLC now owns 329,514 shares of the medical research company’s stock valued at $56,176,000 after purchasing an additional 269,861 shares during the last quarter. Zeke Capital Advisors LLC boosted its position in Amgen by 35.2% during the first quarter. Zeke Capital Advisors LLC now owns 16,459 shares of the medical research company’s stock valued at $2,806,000 after purchasing an additional 4,286 shares during the last quarter. Finally, Mackay Shields LLC acquired a new stake in Amgen during the first quarter valued at $38,479,000. 77.23% of the stock is owned by institutional investors.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $184.27, for a total transaction of $281,011.75. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, topping analysts’ consensus estimates of $3.52 by $0.31. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.27 earnings per share. analysts anticipate that Amgen, Inc. will post 13.95 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 7th. Stockholders of record on Friday, August 17th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Thursday, August 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.69%. Amgen’s payout ratio is presently 41.97%.
A number of analysts recently issued reports on the company. Jefferies Financial Group set a $220.00 price objective on Amgen and gave the company a “buy” rating in a research report on Thursday. Wells Fargo & Co reissued a “neutral” rating and set a $197.00 price objective on shares of Amgen in a research report on Wednesday, August 29th. Oppenheimer reissued a “buy” rating and set a $224.00 price objective on shares of Amgen in a research report on Tuesday, August 28th. Cann reissued a “buy” rating and set a $224.00 price objective on shares of Amgen in a research report on Monday, July 30th. Finally, Morningstar set a $198.00 target price on Amgen and gave the company a “neutral” rating in a report on Monday, July 30th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $202.76.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Read More: Investing in Growth Stocks
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.